Kidney Disease & Nephrology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

This Phase 3 trial is testing a new combination pill of BI 690517 with empagliflozin for adults living with chronic kidney disease. The study includes participants with or without type 2 diabetes who may already be using common kidney medications. If successful, this treatment could slow the progression of kidney disease and reduce heart-related complications, offering a new option for protecting both kidney and heart health.

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

This Phase 3 study is exploring the use of a new cell therapy called REACT for adults who have both type 2 diabetes and chronic kidney disease. The therapy aims to improve kidney function and slow disease progression. Recruiting worldwide, this trial may provide a novel treatment approach that targets the underlying damage in diabetic kidney disease.

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

This Phase 3 trial is testing sotagliflozin, a drug designed to slow the decline of kidney function in people with type 1 diabetes and diabetic kidney disease. The study, recruiting in the US and Canada, includes education and monitoring to help reduce risks such as diabetic ketoacidosis. Positive results could bring a valuable new treatment to help protect kidney health in this group.

Pentoxifylline in Diabetic Kidney Disease

This Phase 4 trial is investigating pentoxifylline, a pill that may slow kidney damage and delay death in patients with diabetic kidney disease. Conducted across 40 VA hospitals in the US with over 2300 participants, the study is active but not currently recruiting. Success here could offer an additional treatment to help preserve kidney function in diabetes.

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

This Phase 3 trial is focused on children aged 6 months to under 18 years who have chronic kidney disease with proteinuria, a condition that can cause kidney damage. The study is testing finerenone, a new oral medication, to learn about its safety and effectiveness when taken alongside standard treatments. If successful, it could provide a new way to reduce kidney damage in children.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.